262 related articles for article (PubMed ID: 33428178)
21. Opicapone for the treatment of Parkinson's disease: a review.
Feldman M; Margolesky J
Int J Neurosci; 2023 May; 133(5):532-543. PubMed ID: 33980110
[No Abstract] [Full Text] [Related]
22. Effectiveness and safety of different catechol-o-methyl transferase inhibitors for patients with parkinson's disease: Systematic review and network meta-analysis.
Wu W; Lu X; Zhang L; Hong D
Clin Neurol Neurosurg; 2024 Apr; 239():108189. PubMed ID: 38437773
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Opicapone for Motor Fluctuations as an Adjuvant to Levodopa Therapy in Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis.
Kwak N; Park J; Kang HY; Lee MJ; Suh JK; Lee H
J Parkinsons Dis; 2022; 12(3):773-783. PubMed ID: 35180134
[TBL] [Abstract][Full Text] [Related]
24. Clinical pharmacology review of opicapone for the treatment of Parkinson's disease.
Fabbri M; Rosa MM; Ferreira JJ
Neurodegener Dis Manag; 2016 Oct; 6(5):349-62. PubMed ID: 27599671
[TBL] [Abstract][Full Text] [Related]
25. Opicapone versus entacapone: Head-to-head retrospective data-based comparison of healthcare resource utilization in people with Parkinson's disease new to catechol-O-methyltransferase (COMT) inhibitor treatment.
Harrison-Jones G; Marston XL; Morgante F; Chaudhuri KR; Castilla-Fernández G; Di Foggia V
Eur J Neurol; 2023 Oct; 30(10):3132-3141. PubMed ID: 37489574
[TBL] [Abstract][Full Text] [Related]
26. Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys.
Bonifácio MJ; Sousa F; Soares-da-Silva P
Eur J Pharmacol; 2021 Feb; 892():173742. PubMed ID: 33220276
[TBL] [Abstract][Full Text] [Related]
27. Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review.
Katsaiti I; Nixon J
J Parkinsons Dis; 2018; 8(2):217-231. PubMed ID: 29614697
[TBL] [Abstract][Full Text] [Related]
28. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
Najib J
Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.
Reichmann H; Boas J; Macmahon D; Myllyla V; Hakala A; Reinikainen K;
Acta Neurol Scand; 2005 Jan; 111(1):21-8. PubMed ID: 15595934
[TBL] [Abstract][Full Text] [Related]
30. Is there a difference between levodopa/ dopa-decarboxylase inhibitor and entacapone and levodopa/dopa-decarboxylase inhibitor dose fractionation strategies in Parkinson's disease patients experiencing symptom re-emergence due to wearing-off? The Honeymoon Study.
Destée A; Rérat K; Bourdeix I
Eur Neurol; 2009; 61(2):69-75. PubMed ID: 19039224
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.
Bonifácio MJ; Torrão L; Loureiro AI; Palma PN; Wright LC; Soares-da-Silva P
Br J Pharmacol; 2015 Apr; 172(7):1739-52. PubMed ID: 25409768
[TBL] [Abstract][Full Text] [Related]
32. Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
Lees AJ; Ferreira J; Rascol O; Poewe W; Rocha JF; McCrory M; Soares-da-Silva P;
JAMA Neurol; 2017 Feb; 74(2):197-206. PubMed ID: 28027332
[TBL] [Abstract][Full Text] [Related]
33. Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions.
Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P
Eur J Neurol; 2019 Jul; 26(7):953-960. PubMed ID: 30681754
[TBL] [Abstract][Full Text] [Related]
34. Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations in Parkinson's disease: a systematic review and meta-analysis.
Żegleń M; Śladowska K; Kawalec P; Brzostek T
J Comp Eff Res; 2022 Aug; 11(12):889-904. PubMed ID: 35758044
[No Abstract] [Full Text] [Related]
35. A 12-month prospective real-life study of opicapone efficacy and tolerability in Emirati and non-White subjects with Parkinson's disease based in United Arab Emirates.
Metta V; Ibrahim H; Muralidharan N; Rodriguez K; Masagnay T; Mohan J; Lacsina A; Ahmed A; Benamer HTS; Chung-Faye G; Mrudula R; Falup-Pecurariu C; Rodriguez-Blazquez C; Borgohain R; Goyal V; Bhattacharya K; Chaudhuri KR
J Neural Transm (Vienna); 2024 Jan; 131(1):25-30. PubMed ID: 37798410
[TBL] [Abstract][Full Text] [Related]
36. Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort.
Damier P; Viallet F; Ziegler M; Bourdeix I; Rerat K
Eur J Neurol; 2008 Jul; 15(7):643-8. PubMed ID: 18582341
[TBL] [Abstract][Full Text] [Related]
37. Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease.
Brooks DJ; Leinonen M; Kuoppamäki M; Nissinen H
J Neural Transm (Vienna); 2008 Jun; 115(6):843-9. PubMed ID: 18259682
[TBL] [Abstract][Full Text] [Related]
38. Effect of Opicapone Tablets on Levodopa and 3-O-Methyldopa Pharmacokinetics in Healthy Japanese Subjects: Phase 1 Study.
Nomoto M; Takeda A; Iwai K; Nishimura A; Hattori N
Clin Pharmacol Drug Dev; 2021 Feb; 10(2):180-189. PubMed ID: 32416054
[TBL] [Abstract][Full Text] [Related]
39. Opicapone for the treatment of Parkinson's disease.
Rodrigues FB; Ferreira JJ
Expert Opin Pharmacother; 2017 Mar; 18(4):445-453. PubMed ID: 28234566
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson's disease patients treated with levodopa/carbidopa.
Hansen RN; Suh K; Serbin M; Yonan C; Sullivan SD
J Med Econ; 2021; 24(1):563-569. PubMed ID: 33866942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
